Every 8-K that NORTHWEST BIOTHRPUTCS INC (NWBO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NWBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NWBO filings page.
Northwest Biotherapeutics, Inc. entered into a $4.9 million convertible promissory note with YA II PN, Ltd. The note has a 12‑month term, carries a 5% Original Issue Discount, bears no interest, and requires repayment of all outstanding amounts at maturity. During its term, the holder may convert the note at a small discount to the then prevailing market price. The company plans to use the proceeds for general corporate purposes, including its lead product and in‑licensed portfolios.
The company and Yorkville also set up a new standby equity subscription agreement, available after the note is repaid or converted. It allows Northwest Biotherapeutics, at its discretion, to require Yorkville to subscribe for up to $50 million of common shares over a 24‑month term at a small discount to market. The company has no obligation to use this facility and can cancel it after the note is repaid or converted. Yorkville additionally received a warrant to purchase up to $2 million of shares at $0.205 per share, and the prior standby equity subscription agreement was cancelled.
Northwest Biotherapeutics, Inc. reported that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed the company’s Marketing Authorisation Application for DCVax-L for glioblastoma remains under its initial regulatory review. MHRA stated the application has not been refused, withdrawn or appealed and continues to progress towards a first regulatory decision.
The company categorically refutes circulating rumors that the application was rejected. It notes these rumors intensified after presenting significant statistical Phase 3 data for DCVax-L at the British Neuro-Oncology Society Annual Meeting and states its belief that the rumors appear linked to various forms of stock manipulation following positive developments.
Northwest Biotherapeutics, Inc. completed the acquisition of Advent BioServices Ltd., its UK-based contract development and manufacturing partner for the DCVax® product platform, making Advent a wholly owned subsidiary. The buyer and seller are related parties through the Company’s Chairperson and CEO, Linda Powers.
The consideration includes a purchase price of approximately $1.9 million (£1.4 million) plus payment of about $8.3 million of accounts payable owed to Advent, with certain excluded payables of about $0.7 million retained by the seller. Payments are due in installments over two years, starting three months after closing, with unpaid balances accruing 7.5% annual interest.
At closing, Advent returned 12 million Northwest Biotherapeutics common shares and 5.5 million stock options previously issued for services; the shares were retired to treasury and the options cancelled. The Company also obtained an SEC waiver under Rule 3-13 of Regulation S-X, so it will not provide separate Advent financial statements or pro forma financial information for this acquisition.
Northwest Biotherapeutics, Inc. has agreed to settle a Delaware Court of Chancery lawsuit over option awards granted to management and directors in 2020. Under the Settlement Agreement, the company’s insurance carriers will pay $2.25 million to the company and 17% of the challenged 2020 stock options will be cancelled, resolving all claims between the parties.
The lead plaintiff intends to ask the court for up to $3,500,000 in attorneys’ fees and expenses, which would be paid separately by the company’s insurers. The agreement and any fee award must be approved at a hearing scheduled for March 16, 2026 at the Leonard L. Williams Justice Center in Wilmington, Delaware.
Northwest Biotherapeutics, Inc. reported the results of its annual stockholder meeting held on December 29, 2025. A quorum was reached, with 1,192,487,345 shares representing 77.4% of the total combined voting power present in person or by proxy.
Stockholders, voting common and preferred shares as a single class, elected Pat Sarma to a new three-year term as a Class II director and ratified Cherry Bekaert LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
They also approved an amendment to the Certificate of Incorporation to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares, and gave advisory approval to the Company’s executive compensation. On December 30, 2025, the Company filed the Certificate of Amendment in Delaware to effect the authorized share increase.
Northwest Biotherapeutics, Inc. entered into a $5 million convertible promissory note financing with YA II PN, Ltd. The company plans to use the cash for construction and equipment for its first Grade C manufacturing suite at its Sawston, UK facility, and for ongoing operations. The note has a 12-month term with no payments due until maturity, carries a 5% original issue discount, and does not bear interest.
During the term, the note is convertible at the holder’s option at a small discount to the then prevailing market price. Conversion amounts are generally limited to about one fifth of the $5 million note in any calendar month, unless the conversion price is above $0.29. The agreement includes customary default provisions.
Northwest Biotherapeutics (NWBO) entered into a $5,505,000 commercial loan with Streeterville Capital, LLC. The loan has a 22‑month term, bears 8% annual interest, and includes a 10% original issue discount. There are no repayments for the first eight months, with repayments beginning on June 26, 2026.
After repayments begin, the note amortizes over 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. The company may prepay at its election, subject to a 10% prepayment charge, and the agreement contains customary default and acceleration provisions. Proceeds will support ongoing business operations.
Northwest Biotherapeutics (NWBO) closed its acquisition of Advent BioServices, which is now a wholly owned subsidiary. The deal transfers Advent’s fixed assets, including extensive cryostorage and related equipment, plus intellectual property and other intangibles, to NWBO.
No new shares are being issued. Instead, 19 million previously issued NWBO securities are reverting to the company, comprising 13.5 million shares and 5.5 million options. Cash consideration consists of a payment of £1.4 million and the net amount of accounts payable due to Advent for prior services. Payments will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L. Installments begin 90 days after the October closing, and the net accounts payable is determined as of the closing date.
Northwest Biotherapeutics (NWBO) reported that it filed a new Form S-3 shelf registration on October 23, 2025 to replace its existing shelf. Shelf registrations expire three years from effectiveness; the company’s current shelf became effective on October 25, 2022 and therefore expires on October 25, 2025. Filing the new shelf before expiration maintains an ongoing effective registration framework.
The company’s common stock trades on the OTCQB under the symbol NWBO.
Northwest Biotherapeutics (NWBO) announced a settlement agreement, set out in a binding Term Sheet, to resolve Delaware Court of Chancery litigation over 2020 option awards to management and directors. Under the agreement, 17% of the challenged 2020 options will be cancelled, and the Company’s insurance carriers will pay $2.25 million to the Company.
The parties will use best efforts to complete definitive settlement documents within thirty days, and the settlement is subject to Court approval. The Lead Plaintiff intends to apply for an award of attorneys’ fees and expenses. Under the settlement, the $2.25 million payment is not to be used for any fee award; it is currently anticipated that any fee award will be paid separately by the Company’s insurers.